GlassScriptPhysician profile
Stephanie Roberts
NPI 1144393257
$636.63
in general payments reported to CMS, 2019-2025
19 companies · $81.10 in 2025
The $81.10 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.49 · 2022: $62.37 · 2023: $224 · 2024: $223 · 2025: $81.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.82 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $84.41 | 2021-2024 | Farxiga |
| Exact Sciences Corporation | $67.12 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $60.06 | 2021-2025 | Korlym |
| Cardiva Medical, INC. | $50.77 | 2023 | Cardiva Vascade 6/7f Vcs |
| Abbott Laboratories | $49.95 | 2023 | Freestyle Insulinx |
| Novo Nordisk INC | $42.59 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $42.36 | 2023 | Jardiance, Emgality |
| Sanofi Pasteur INC. | $34.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.43 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.51 | 2024 | Jardiance |
| Dexcom, INC. | $21.11 | 2024 | Dexcom G6 Transmitter |
| Itamar Medical INC | $19.39 | 2023 | Watchpatone |
| Bayer Healthcare Pharmaceuticals INC. | $16.50 | 2022 | |
| Abbvie INC. | $16.24 | 2023 | |
| Glaxosmithkline, LLC. | $15.61 | 2024 | Arexvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $14.20 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $14.09 | 2024 | Inspire |
| Pfizer INC. | $13.76 | 2024 | |
| Merck Sharp & Dohme LLC | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.